Second primary cancer after female breast cancer: Familial risks and cause of death

Zheng, Guoqiao; Hemminki, Akseli; Försti, Asta; Sundquist, Jan; Sundquist, Kristina; Hemminki, Kari

doi:10.1002/cam4.1899

Cited by 16 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer (BC) is a complex multigene disease and developed from the genetic defect or acquired DNA damage, and involves multiple cross-talks pathway, such as triple-negative breast cancer (TNBC) is more likely to carry BRCA1/2 mutations, with high metastasis, recurrence rates and shorter overall survival rates 1 , 2 , 3 , 4 . According to the statistics of international cancer research institute, breast cancer has become the highest incidence of cancer among women in the world 5 . Currently, the main treatment for BC patients is chemotherapy with small-molecule drugs in addition to radiotherapy and surgery 6 , 7 , 8 .…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Chang

Sun

Shi

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

This study was aimed to design the first dual-target small-molecule inhibitor co-targeting poly (ADP-ribose) polymerase-1 (PARP1) and bromodomain containing protein 4 (BRD4), which had important cross relation in the global network of breast cancer, reflecting the synthetic lethal effect. A series of new BRD4 and PARP1 dual-target inhibitors were discovered and synthesized by fragment-based combinatorial screening and activity assays that together led to the chemical optimization. Among these compounds, 19d was selected and exhibited micromole enzymatic potencies against BRD4 and PARP1, respectively. Compound 19d was further shown to efficiently modulate the expression of BRD4 and PARP1. Subsequently, compound 19d was found to induce breast cancer cell apoptosis and stimulate cell cycle arrest at G1 phase. Following pharmacokinetic studies, compound 19d showed its antitumor activity in breast cancer susceptibility gene 1/2 ( BRCA1/2 ) wild-type MDA-MB-468 and MCF-7 xenograft models without apparent toxicity and loss of body weight. These results together demonstrated that a highly potent dual-targeted inhibitor was successfully synthesized and indicated that co-targeting of BRD4 and PARP1 based on the concept of synthetic lethality would be a promising therapeutic strategy for breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Chang

Sun

Shi

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…A cohort of 2,116,163 patients was identified in a study, 170,865 of whom (8.1%) developed a second primary malignancy, and more than 50% of the patients with 2 incident cancers died of their secondary malignancy (4). Another study showed that 17.0% (14,952/87,752) of breast cancer patients developed second primary cancer after a median follow-up of 5 years (5). Due to the complicated and changeable diagnosis and treatment of multiple primary tumors, there is no unified diagnosis and treatment standard at present.…”

Section: Introductionmentioning

confidence: 99%

The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies

Yang¹,

Xie²,

Liu³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: For patients with previously diagnosed dual primary tumors, it is usually difficult to determine the diagnosis and treatment of stage IV recurrence. The study was to explore the influences of 18 F-fluoroestradiol positron emission tomography/computed tomography ( 18 F-FES PET/CT) in the diagnosis of estrogen receptor (ER) positive breast cancer combined with other primary tumor with distant metastases.Methods: Multidisciplinary team were organized to explore the definite clinical value of 18 F-FES PET/ CT in stage IV patients suffered from ER-positive breast cancer and another primary tumor synchronously or metachronously. Thirty-two female patients were retrospectively analyzed who underwent 18 F-FES PET/ CT scans in our center. Before and after reading 18 F-FES reports, the team members from department of surgery, oncology and radiotherapy should make decisions of management strategy.Results: Totally, the multidisciplinary team completed the management decision-making of the 32 patients before and after 18 F-FES PET/CT scans. 87.5% (n=28) of the patients were considered to benefit from 18 F-FES reports for diagnosis and treatment decisions. Out of the 28 patients, 7 patients (7/32, 21.9%) were considered to definitely change the management strategies while 12 patients (12/32, 37.5%) was instructive to develop management plans after the scan. The other 9 patients were suggested reassuring decision-making process by 18 F-FES PET/CT. Conclusions: 18 F-FES PET/CT scans have clinical effects on diagnosis and treatment strategies of stage IV patients suffered from ER-positive breast cancer and another primary tumor.

show abstract

“…The aim of the present study was to estimate the influence of family history on the risk of SPCs in patients with primary invasive or in situ SCC. We also hypothesized that family history of cancer X increases the risk for cancer X to be an SPC, as has been observed for some other cancers . We additionally tested if family history of skin cancer increases risk of second SCC after nonskin cancer.…”

mentioning

confidence: 96%

“…We also hypothesized that family history of cancer X increases the risk for cancer X to be an SPC, as has been observed for some other cancers. [17][18][19][20][21] We additionally tested if family history of skin cancer increases risk of second SCC after nonskin cancer. Some recent results on prostate, breast and ovarian cancers suggest that the cause of death in patients with SPC is often the SPC; 18,19,22 therefore, we assessed survival in patients with SCC who were diagnosed with SPC and whether survival is influenced by family history of SPC.…”

mentioning

confidence: 99%

Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Summary Background Patients with squamous cell skin cancer (SCC) have an excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in patients with SCC is not known. Objectives To quantify the risk of family history on SPCs in patients with SCC and estimate survival probabilities of patients with SPCs depending on family history. Methods With 13 945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios (HRs) were assessed using a multivariable Cox proportional‐hazards model. Results Family history of invasive SCC increased risk of second invasive SCC [RR = 42·92, 95% confidence interval (CI) 33·69–50·32] compared with risk without family history (RR 19·12, 95% CI 17·88–21·08). Family history of any nonskin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC (RRFH = 1·48, 95% CI 1·35–1·61 vs. RRno FH = 1·40, 95% CI 1·32–1·48); significant increases were observed for seven different nonskin cancers. Most results were replicated for in situ SCC. SPC was deleterious for survival irrespective of family history; HR for patients with SPC was 4·28 (95% CI 3·83–4·72) vs. those without SPC (1·04). Conclusions Family history of nonskin cancer was associated with approximately a doubling of risk for SPCs in patients with SCC. SPC increases the death rate in patients with SCC 3–4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs. What's already known about this topic? Second primary cancers (SPCs) are frequently diagnosed in patients with invasive and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a link to immune dysfunction. Family history of cancer is a risk factor for practically all first primary cancers but whether it also influences risk of SPCs in patients with SCC is not known. The possible influence of family history on survival in patients with SCC remains to be established. Linked Comment: Youlden and Baade. Br J Dermatol 2020; 183:414–415.

show abstract

Second primary cancer after female breast cancer: Familial risks and cause of death

Cited by 16 publications

References 30 publications

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies

Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer

Contact Info

Product

Resources

About